a melanoma researcher at the University of Pittsburgh. “We finally have a randomized controlled trial that is positive.” Finalized phase 1 results of a BRAF inhibitor, developed by the ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

BRAF positive melanoma produces too much of a protein called BRAF. This also affects other proteins such as MEK. Both of these can make the cancer grow. Targeted cancer drugs work by blocking the ...

BRAF positive melanoma produces too much of the BRAF protein. This also affects other proteins such as MEK. Both of these can make the cancer grow. Targeted cancer drugs work by blocking the proteins.

This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

Patients with melanoma and colorectal cancer ... currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

The researchers loaded the platform with two pairs of drugs approved by the FDA: BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma ...

This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called SEACRAFT-2 as part of a combination therapy with Mikinist (trametinib) from Novartis to treat NRASm melanoma. The primary ...

Amtagvi is indicated for intravenous infusion to treat advanced unresectable or metastatic melanoma in ... and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.